A new belly injection reportedly cut the most dangerous belly fat by 12% in early human trials, signaling a potential win for patient choice and real health results.
Story Highlights
- Early Phase 2 trials found a 12.01% average drop in visceral fat with CBL-514, versus a 5.68% rise on placebo.
- Magnetic resonance imaging, not bathroom scales, measured visceral fat changes.
- Randomized, placebo-controlled human trials support the drug’s fat-reduction effect in treated areas.
- Published data so far focuses more on subcutaneous fat than visceral fat durability.
What The Trials Reported About Visceral Fat
Fox News reported that people who received CBL-514 injections every three weeks for up to 12 weeks saw an average 12.01% reduction in visceral fat, measured by magnetic resonance imaging four weeks after the last dose. The placebo group reportedly saw a 5.68% increase over the same period. The report described dosing up to 600 milligrams and stated that the comparison came from two Phase 2 studies with a controlled design.
Visceral fat is the deep belly fat around organs that raises heart and diabetes risk. Measuring it by magnetic resonance imaging matters because it looks inside, not just at weight. The report frames the change as a direct look at organ-surrounding fat. That is why this result caught attention. The claim sits within real human trials, which is stronger than lab hype, though the follow-up window reported was short at four weeks post-treatment.
What Is Firmly Published So Far
A peer-reviewed Phase 2 study has already shown CBL-514 reduced abdominal subcutaneous fat in the treated area versus placebo. Seventy-six people were randomized two-to-one, and the between-group fat-volume differences at four and eight weeks were large and statistically significant, with very strong P values. That paper focused on fat under the skin, not visceral fat. It adds weight to the idea that the injection acts on fat where it is used, in a controlled human setting.
Clinical-trial listings describe randomized, single-blind, placebo-controlled Phase 2 studies with dozens to over a hundred participants. Those entries support that the sponsor ran structured human studies designed to compare CBL-514 with placebo. The listings emphasize subcutaneous fat reduction as the main goal. That matches the published paper’s focus and helps explain why the visceral-fat claim is new to many readers and still building its public record.
Why This Could Matter For Health, Not Just Looks
Visceral fat drives many health problems. When it falls, markers linked to diabetes and heart disease can also improve over time. Lifestyle trials and reviews link a roughly ten percent drop in visceral fat with better insulin resistance and lower long-term risk trends. That context explains why a twelve percent average visceral-fat change, if repeated and durable, could matter for everyday health, not only appearance. The key test is whether results last and translate into better lab and clinical outcomes.
Americans want real tools that improve health without heavy mandates or one-size-fits-all rules. A targeted shot that reduces risky fat, measured by imaging, aligns with patient freedom and practical prevention. If future trials confirm sustained benefit and clear safety, this approach could sit beside diet, exercise, and other therapies. The Food and Drug Administration will need full data to judge long-term effects, safety, and proper use, as with any new treatment.
What We Still Need To See From Researchers
Researchers have shared the headline visceral-fat figure and the timing of scans, but they have not, in public materials, provided the sample size, confidence range, or exact protocol for that specific magnetic resonance imaging endpoint. The published paper covers subcutaneous fat, not the visceral-fat numbers. The next steps are simple: release the complete analysis, extend follow-up to six to twelve months, and report metabolic measures like insulin sensitivity alongside imaging.
NEW TREATMENT: An experimental injection called CBL-514 slashed dangerous visceral fat — the deep abdominal fat wrapped around internal organs — by 12% in early human trials, while patients on a placebo saw their visceral fat increase nearly 6%.
The drug works by selectively… pic.twitter.com/23PMe6LG62
— Fox News Health (@foxnewshealth) October 12, 2026
For now, the takeaway is clear and encouraging: a randomized program using CBL-514 showed meaningful fat changes measured inside the abdomen, and a peer-reviewed study already confirms subcutaneous fat reduction in the treated area. That combination points to a real effect that deserves full, transparent reporting. In a health system too often driven by fads and mandates, results that are measured, targeted, and patient-centered are the kind of progress worth watching closely.
Sources:
clinicaltrials.gov, academic.oup.com, fda.gov
